X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://businessmicro.in/business/clirnet-teams-up-with-african-medical-associations-to-revolutionize-healthcare-education/
https://www.globenewswire.com/news-release/2024/04/23/2867327/0/en/Press-Release-Rilzabrutinib-LUNA-3-phase-3-study-met-primary-endpoint-in-immune-thrombocytopenia.html
https://www.globenewswire.com/news-release/2024/02/24/2834723/0/en/Press-Release-Phase-2-results-demonstrate-rilzabrutinib-rapidly-reduced-itch-severity-and-significantly-improved-disease-activity-in-adults-with-chronic-spontaneous-urticaria.html
https://health.economictimes.indiatimes.com/news/pharma/this-drug-for-blood-disorder-shows-promise-in-phase-1-2-clinical-trial/90912678
https://www.sanofi.com/en/media-room/press-releases/2022/2022-04-14-07-00-00-2422388
https://www.globenewswire.com/news-release/2022/04/14/2422388/0/en/Press-Release-Positive-Phase-1-2-study-results-of-rilzabrutinib-in-people-with-immune-thrombocytopenia-published-in-The-New-England-Journal-of-Medicine.html
https://www.fiercebiotech.com/biotech/sanofi-hit-by-filing-delays-for-key-drugs-drops-early-sangamo-thalassemia-asset
https://www.biospace.com/article/sanofi-shuttering-principia-s-san-francisco-labs-days-after-btk-inhibitor-flunks-trial/?s=71
https://www.fiercebiotech.com/biotech/sanofi-s-btk-inhibitor-flunks-phase-3-autoimmune-trial-delivering-blow-to-3-7b-biotech-bet
https://www.pharmatimes.com/news/sanofis_oral_btk_inhibitor_rilzabrutinib_fails_phase_iii_trial_1376448
https://www.globenewswire.com/news-release/2020/11/24/2132744/0/en/Patient-Enrollment-Concluded-Early-in-PEGASUS-Phase-3-Pemphigus-Trial-for-Rilzabrutinib.html
Market Place
Share 
